The precise role of CD4 T cell turnover in maintaining HIV persistence during antiretroviral
therapy (ART) has not yet been well characterized. In resting CD4 T cell subpopulations …

Combination antiretroviral therapy controls but does not cure HIV-1 infection because a
small fraction of cells harbor latent viruses that can produce rebound viremia when therapy …

Introduction Viral remission after analytical treatment interruption (ATI), termed post‐
treatment control, has been described in a small proportion of HIV‐positive patients. This …

The human immunodeficiency virus (HIV) infection of the immune cells expressing the
cluster of differentiation 4 cell surface glycoprotein (CD4+ cells) causes progressive decline …

Approaches to deplete persistent HIV infection are needed. We investigated the combined
impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous …

Antiretroviral inhibitors that are used to manage HIV infection/AIDS predominantly target
three enzymes required for virus replication: reverse transcriptase, protease, and integrase …

The HIV-1 reservoir consists of latently infected cells that persist despite antiretroviral
therapy (ART). Elucidating the proviral genetic composition of the reservoir, particularly in …

Three decades of extensive work in the HIV field have revealed key viral and host cell
factors controlling proviral transcription. Various models of transcriptional regulation have …

The latent reservoir for human immunodeficiency virus type 1 (HIV-1) in resting CD4+ T cells
is a major barrier to cure. The dimensions of the reservoir problem can be defined with 2 …

More than 50% of the HIV-1 latent reservoir is maintained by clonal expansion. The clonally
expanded HIV-1-infected cells can contribute to persistent nonsuppressible low-level …